AbZelectPRO™ – Powering the Fast Track from DNA to Clinic

Wednesday, March 4, 2026 at 11:25 AM to 11:50 AM · 25 min. (US/Pacific)
Biologics Manufacturing
Presentation
Theater 5

Information

Our fully integrated AbZelectPRO™ platform enables the rapid delivery of stable, high-producing cell lines to support the production of antibodies and more difficult-to-express proteins. The platform combines our AbZelectPRO™ CHO-K1 and AbZelectPRO™-KO GS knockout cell lines together with ProteoNic’s 2G UNic® vector technology and, supported by our comprehensive analytics capabilities, provides a state-of-the-art offering to support our clients as they transition from R&D into preclinical and clinical development.

Abzena
415
Abzena is the leading end-to-end bioconjugate (ADCs, AOCs, RDCs) and complex biologics CDMO + CRO. From discovery through commercial, we support customers with fully integrated programs or individual services that de-risk and streamline the development of new medicines for patients in need. With over two decades of experience, 2000+ conjugates developed and over 200+ cell lines developed, we have the expertise and technical know-how to rapidly progress your biopharmaceutical to IND and beyond. And with footholds in the US and UK, we offer a simplified and secure supply chain. Fully integrated CDMO+CRO support across multiple modalities: -Monoclonal Antibodies (mAbs) -Antibody-Drug Conjugates (ADCs) -Antibody-Oligonucleotide Conjugates (AOCs) -Radionuclide Antibody-Conjugates (RACs) & Radionuclide Drug-Conjugates (RDCs) -Bispecific Antibodies (bsAbs) -Fusion Proteins -Cytokines -Recombinant & Conjugate Vaccines -Nanoparticles With Capabilities Ranging From: • Early-Stage Research & Discovery, Design and Lead Selection • Robust Analytics, Bioassays, and Immunogenicity • Bioconjugation & Chemistry • Antibody Engineering and Developability • Mammalian Cell Line Development • Linker Payload Design and Synthesis • Analytical Method & Formulation Development • Process Development and cGMP Manufacturing up to 2000L • Technology Transfer & Scale-Up • Regulatory Support - Over 24 years of experience developing 2000+ conjugations, 1400+ linker-payloads synthesized and 200+ cell lines -Champion Award Winner in Global Biologics at the 2025 CDMO Leadership Awards - Unique end-to-end value proposition ranging from antibody discovery to clinical-scale GMP biologic drug substance manufacture - Scientific expertise to deliver at high quality, low cost and compressed timelines - Global customer base, including most of the top 20 biopharmaceutical companies -Supply chain security with fully integrated US & UK facilities that can handle highly potent and cytotoxic molecules. - 14 products utilizing Abzena’s technologies in clinical trials - Biologics discovery, design, optimization, characterization, lead selection, cell line development, process development & GMP manufacture for supply from preclinical through commercial scale. - Bioconjugate (including ADCs, AOCs, RDCs) discovery, design, optimization, characterization, lead selection, cell line development, process development & GMP manufacture for supply from preclinical through commercial scale. - Synthesis, analysis, and GMP manufacture of APIs, payloads, and highly potent compounds (HPAPI) and cytotoxic - Discovery to Phase II accelerated development for antibody-drug conjugates including antibodies, linkers and payloads. -Tech transfer and commercial scale manufacturing up to 2000L for biologics and bioconjugates

Log in

See all the content and easy-to-use features by logging in or registering!